Polar Capital Holdings Plc 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 08:01 am Purchase | 2025-06-30 | 13G | Enliven Therapeutics, Inc. ELVN | Polar Capital Holdings Plc | 2,536,881 5.170% | 147,213 (+6.16%) | Filing |
| 2025-02-14 09:17 am Sale | 2024-12-31 | 13G | Enliven Therapeutics, Inc. ELVN | Polar Capital Holdings Plc | 2,389,668 4.890% | -298,129 (-11.09%) | Filing |
| 2024-11-13 5:55 pm Purchase | 2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN | Polar Capital Holdings Plc | 2,687,797 5.690% | 2,687,797 (New Position) | Filing |